Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

M. O’Reilly, Eileen; Oh, Do‐Youn; C. Dhani, Neesha; J. Renouf, Daniel; Ah Lee, Myung; Sun, Weijing; A. Fisher, George; F. Hezel, Aram; Chang, Shao-Chun; Vlahovic, Gordana; Takahashi, Osamu; Yang, Yin; Fitts, David; Agop Philip, Philip

doi:10.1001/jamaoncol.2019.1588

Public

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Published in JAMA Oncology • Jul 18, 2019

Authors:

Eileen M. O’Reilly

Do‐Youn Oh

Neesha C. Dhani

Abstract

IMPORTANCE: New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC. OBJECTIVE: To evaluate the safety and efficacy of the anti-PD-L1 (programmed death-ligand 1) antibody...

Subject

Durvalumab

Medicine

Tremelimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!